PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
AetnaAll Plans · Coverage · Radiology · Ophthalmology, Radiology, NeurologyMedium impact

Optic Nerve and Retinal Imaging Methods (CPB 0344, reviewed 2026-10-20)

Effective date
Not stated in the notice
Identified
Oct 23, 2026

Summary

Aetna's Clinical Policy Bulletin 0344 covers optic nerve and retinal imaging methods. Aetna considers these methods medically necessary for documenting the appearance of the optic nerve head and retina in listed diagnoses, including glaucoma, glaucoma suspects, diabetic retinopathy and age-related macular degeneration, and considers OCT angiography (OCTA) medically necessary as an alternative to intravenous fluorescein angiography (IVFA) for listed conditions. Aetna considers routine screening of asymptomatic persons for glaucoma and other retinal diseases, and OCTA for diagnosing and monitoring glaucoma, experimental, investigational or unproven. The policy history lists a last review date of 10/20/2026.

Get alerts when payers change rules like this one

We check Aetna and other payers every day and email you when a change matches your specialty and state.

Get Aetna alertsPolicy Monitoring is free. No card required.

What to do

Action · 6 steps
01Billing team: Do not bill optic nerve imaging for glaucoma more than once per year, since the source considers that not medically necessary.
02Do not bill both OCTA and IVFA for the same indication, or both OCT and OCTA for the same indication, since the source considers that not medically necessary.
03Do not schedule or bill the uses the source lists as experimental, investigational or unproven, including routine screening of asymptomatic persons for glaucoma and other retinal diseases, OCTA for diagnosing and monitoring glaucoma, and remote OCT monitoring.
04Do not bill CPT 0469T, 0604T, 0605T or 0606T for indications the CPB lists as not covered.
05Before starting chloroquine, hydroxychloroquine or vigabatrin therapy, complete a baseline optic nerve and retinal imaging study, which the source considers medically necessary.
06Annual screening should begin after 5 years of use, or sooner with unusual risk factors.

Codes mentioned

921339213492137

Original notice

Optic Nerve and Retinal Imaging Methods (CPB 0344, reviewed 2026-10-20)
aetna.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account